Alice Bertaina Bertaina
Hematology/Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Hospitals listed: Lucile Salter Packard Children'S Hsp at Stanford. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Alice Bertaina Bertaina’s office at (650) 498-7200 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Lucile Salter Packard Children'S Hsp at StanfordPalo Alto, CAChildren · Voluntary non-profit - Private · No emergency departmentPart of Stanford Health Care, which runs 3 hospitalsNo overall ratingNo measure marked better or worse than the national rate
Money from drug and device companies
$150 in 2025
| 2025 | 1 | 1 | $150 | $150 |
| 2021 | 2 | 2 | $1,980 | $2,060 |
| 2019 | 1 | 1 | None | $50 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Scientific Affairs | Talvey | $150 | 1 payment
|
See the published payment
| Janssen Scientific Affairs | Consulting · 2025-08-15 | Talvey | $150 |
See earlier years (2021, 2019)
2021: $2,060
| Sobi | Gamifant | $1,980 | 1 payment
|
| Eisai | None | $80 | 1 payment
|
2019: $50
| Sobi | Gamifant | $50 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · An Open-Label, Multi-Center, Phase I/II Study To Assess Safety, Tolerability and Efficacy of Dft383 in Pediatric Participants With Nephropathic Cystinosis · 2025 | Their institution | $39,431 |
| Incyte Corporation · Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects · 2019 | Their institution | $23,005 |
| Incyte Corporation · Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects · 2020 | Their institution | $22,900 |
Professional record
- NPI
- 1386136257
- Licence
- CA SFP000036
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X); Internal medicine (207R00000X); Pediatrics (208000000X)
- Mailing address
- 1000 Welch Rd Ste 301, Palo Alto, CA, 94304
- NPI first listed
- 2018-06-05
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1000 Welch Rd Ste 301, Palo Alto, CA, 94304